Alluvi, previously BI 4744, presents a notable development in weight loss care. This dual stimulator targeting both GLP-1 and GIP targets demonstrates compelling efficacy in clinical studies, possibly surpassing https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/